Xarelto News
Most Popular Xarelto Story
Xarelto - 15 top blockbuster contenders
The drug: Xarelto (rivaroxaban)The disease: CardiovascularThe developers: Bayer and J&JPeak projections: Bayer estimates around $2.87 billion Xarelto has already snagged an approval for Read more...
Latest Headlines
- December 20, 2011
- October 25, 2011
- September 30, 2011
- September 23, 2011
- September 9, 2011
- November 15, 2010
- August 31, 2010
- November 19, 2009
- May 28, 2009
- May 21, 2009
- March 20, 2009
- March 17, 2009
- November 10, 2008
- September 16, 2008
- July 25, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
